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Stellingen behorende tot het proefschrift 
pharmacological aspects of corticotrophinergic and 
vasopressinergic function tests for hpa axis activation
1 The major activatory hpa axis routes can be quantifi ed in terms of 
adrenocorticotrpic hormone (acth) - and cortisol release using relatively 
specifi c pharmacological function tests, either by direct stimulation with 
the peripherally acting agents corticorelin (hcrh) and desmopressin 
(ddavp) or by indirect stimulation with the centrally active drugs 
5-hydroxytryptophan (5-htp) and metoclopramide (this thesis).
2 The combined 5-htp/carbidopa/granisetron function test is a useful 
tool to quantify central serotonin-mediated corticotrophinergic hpa axis 
activation (this thesis). It can be used to study the integrity of the hpa axis 
in health and disease, and to examine the modifi cation of hpa axis function 
by (pharmacological) treatments of (stress-related) psychiatric disorders.
3 It is plausible that serotonin-mediated hpa axis activation causes a 
temporary reduction of glutamate stores in the hypothalamus (this thesis).
4 The dose at which ddavp has few confounding cardiovascular (stress) 
effects is associated with too small and/or insuffi ciently specifi c activation 
to be useful as pharmacological function test to quantify vasopressinergic 
co-activation of the hpa-axis in healthy volunteers (this thesis).
5 Vasopressinergic co-activation of the hpa axis is a dose-dependent function 
of ambient crh concentrations or crha-receptor activation, and can be 
mimicked pharmacologically by the concomitant administration of ddavp 
and low doses hcrh (this thesis).
6 Drugs that are applied as pharmacological function tests induce functional 
changes in (neuro)physiological systems. The magnitude of such changes 
is not only determined by the sensitivity of the system but also by the 
(plasma) concentrations of the function tests drug. The correct interpreta-
tion of effects of a function test therefore requires careful characterization 
of the pharmacokinetic properties of the function test drug.
7 Pharmacologically well-characterized function tests can be applied 
to examine whether hpa axis dysfunction is a pathogenetic factor in 
(stress-related) psychiatric disorders or merely an epiphenomenon of 
such psychopathology.
8 An important handicap of preclinical animal models that predict the 
clinical effects of novel drugs for the treatment of mood disorders, is that 
the majority of such models do not recognize the role of neurotransmitters 
other than the monoamines in the (dys)regulation of mood.
9 Although dolphins and whales are intellectually more superior laboratory 
animals than rodents, they are rather impractical and neither superior 
in human communication nor in demonstrating complex (behavioural) 
symptoms that underly psychiatric disorders in humans (adapted from 
Striedter 2005, Principles of Brain Evolution). 
10 Superfl uous bureaucracy involved in the developmental process of novel 
drugs often discourages fruitful collaboration between the (result driven) 
pharma industry and the (traditionally reserved) academia.  
11 Every psychiatrist that is confronted with a therapy resistent patient, 
should be able to consider basic clinical pharmacological principles in 
discerning true therapy resistance from potentially reversible pharma-
cological treatment complications.
12 If you talk to a man in a language he understands, that goes to his head. 
If you talk to him empathically, that goes to his head all the same but 
activates the necessary neuronal circuits for psychotherapy to be effective 
(adapted from Nelson Rolihlahla Mandela).
